A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.

Migraine Clinical Trial

Official title:

A Proof of Concept Clinical Investigation Designed to Evaluate the Performance of Lumishade® Lens With Frame in Alleviating the Symptoms of Photosensitive Migraine.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04904328
• Other study ID #: LUMIS001
• Secondary ID: ID: 273901
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 30, 2021
• Est. completion date: April 4, 2022

Study information

• Verified date: May 2021
• Source: Mitsui Chemicals, Inc.
• Contact: Yoshito Takeuchi
• Phone: +81-90-4822-4960
• Email: Yoshito.Takeuchi[@]mitsuichemicals.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This proof of concept clinical study will investigate the efficacy of active lens with frame in alleviating the symptoms of migraine which are caused by photosensitivity.

The spectacles cut out blue light wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.

Description:

Patients will be randomised to one of two groups:

Group 1

1. Patients wear sham glasses for 4 weeks

2. Patients have 1 week's washout

3. Patients wear active glasses for 4 weeks

Group 2

4. Patients wear active glasses for 4 weeks

5. Patients have 1 week's washout

6. Patients wear sham glasses for 4 weeks

The study will aim to determine whether wearing the active lens successfully reduces the symptoms of migraine, compared to wearing sham lens.

Assuming a fairly conservative SD in the primary endpoint of 8 points, a total of 56 participants would be required to have 90% power to detect a minimum clinically significant difference of 5 points in a two-sample t-test. Allowing for a 20% drop-out rate, 70 participants would need to be recruited.

Patients will be in the trial for a total of 13 weeks (4 week run-in, two 4 week periods, with 1 week washout in between).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 77
• Est. completion date: April 4, 2022
• Est. primary completion date: January 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Over 18 years old

2. Diagnosis of migraine before the age of 50, confirmed though screening consultation with the patient

3. Willing and able to provide written informed consent

4. Willing to comply with study assessment schedule and patient diary entry

5. Diagnosis of migraine, with or without aura based on the following primary headache characteristics (based on the Revised International Headache Society criteria for migraine headache)

1. At least 5 attacks fulfilling criteria B-D

2. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)

3. Headache has at least two of the following characteristics:

i. unilateral location ii. pulsating quality iii. moderate or severe pain intensity iv. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) d. During headache at least one of the following: i. nausea and/or vomiting ii. photophobia and phonophobia e. Not attributed to another disorder

6. Migraine associated with photophobia i.e. either photic hypersensitivity or photic allodynia or inter-ictal photophobia or migraine triggered by light according to patient or a combination of these 4 factors

7. No expected changes of headache preventative medications after enrolment

Exclusion Criteria:

1. Patients with other light sensitive conditions, such as iritis or retinal disease.

2. Patients who have less than 4 headache days per month

3. Patients who have daily headaches.

4. Pregnant or nursing

5. History of cluster headache or hemiplegic migraine

6. Evidence of seizure or major psychiatric disorder

7. Score of 19 or higher on the BDI

8. Active chronic pain syndrome

9. Cardiac or hepatic disease

10. Have taken any investigational medication within 12 weeks before randomization, or are scheduled to receive an investigational drug

11. Have received Botox injections for any purpose in the head or face region within 3 months of trial onset or scheduled to receive such treatment during the trial

12. Medication overuse as per the revised ICHD-3 IHS criteria

13. Medications that can affect light perception like ethambutol, hydroxychloroquine or amiodarone or any other according to the opinion of the investigator

14. Patients requiring prescription/reading glasses

15. Patients who have not responded to three or more migraine preventive drugs

16. Patients who have a diagnosed neurological disorder that may influence the study according to the investigators

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Device:
• Lumishade® Active Lens
Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring. (Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)
• Lumishade® Sham Lens
Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine. (Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mitsui Chemicals, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Headache Impact Test 6	The primary endpoint is the change in Headache Impact Test (HIT-6) score from end of run-in (Baseline) to end of treatment period following 4 weeks of treatment. The HIT 6 questionnaire is a licensed questionnaire with standardised calculations to assess the responses to the questions in the questionnaire.	up to 13 weeks for each patients participation
Secondary	Patient diary	A headache diary. A headache diary serves to: Monitor the frequency, duration and severity of your headaches over time; Identify patterns that may help determine triggers and improve treatment; Track medication use and response; Maintain long term records of what has worked and what has not	up to 13 weeks for each patients participation